Cetirizine Hydrochloride

CHEMBL1607273 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
461.8 g/mol
LogP
Phase
4

The hydrochloride salt of cetirizine is the standard clinical formulation of this second-generation antihistamine, used for once-daily management of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. It is well absorbed orally and primarily eliminated unchanged by the kidneys. Dose reduction is recommended in patients with renal impairment.

น้ำหนักโมเลกุล

461.8000 g/mol

TPSA

53.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1

InChI

InChI=1S/C21H25ClN2O3.2ClH/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26;;/h1-9,21H,10-16H2,(H,25,26);2*1H

Molecular Formula

C21H27Cl3N2O3

HBD / HBA

3 / 5

พันธะที่หมุนได้

8

อะตอมหนัก

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The hydrochloride salt of cetirizine is the standard clinical formulation of this second-generation antihistamine, used for once-daily management of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. It is well absorbed orally and primarily eliminated unchanged by the kidneys. Dose reduction is recommended in patients with renal impairment.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Cetirizine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1607273. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 55182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.